Trial Shows Safety of Novel KIR-CAR T Therapy in Solid Tumors

Why It Matters

The trial shows that engineered CAR T cells can be safely applied to solid tumors, opening a new therapeutic avenue for cancers with limited options and signaling a shift in cellular immunotherapy development.

Key Takeaways

• SynKIR-110 uses NK‑cell receptors for an on/off CAR T design.
• Phase I trial shows safety with no dose‑limiting toxicities in nine patients.
• Partial response observed at highest dose, disease stabilization in 44% of patients.
• Targets mesothelin, a protein overexpressed in ovarian, mesothelioma, cholangiocarcinoma.
• Verismo Therapeutics, a Penn spin‑out, plans Phase II after enrolling 42 patients.

Pulse Analysis

Cellular immunotherapy has transformed hematologic malignancies, yet solid tumors remain a formidable hurdle due to the hostile tumor microenvironment and T‑cell exhaustion. The KIR‑CAR platform, exemplified by SynKIR‑110, leverages natural‑killer cell receptors in a multi‑chain architecture that activates only upon antigen engagement. This on/off mechanism mimics physiological NK‑cell behavior, potentially mitigating chronic activation‑related toxicity that has limited earlier solid‑tumor CAR T attempts.

In the ongoing STAR‑101 Phase I study, nine heavily pre‑treated patients received escalating doses of SynKIR‑110 targeting mesothelin, a surface protein prevalent on ovarian, mesothelioma and cholangiocarcinoma cells. Safety outcomes were encouraging: no dose‑limiting toxicities, only mild cytokine release syndrome in a third of participants, and no neurotoxicity. Efficacy signals emerged as disease stabilization in four patients and a durable partial response at the top dose, accompanied by dose‑dependent CAR T expansion in peripheral blood. These early data suggest that the engineered on/off switch can sustain T‑cell activity while preserving patient tolerability.

The implications extend beyond a single trial. If Verismo Therapeutics can confirm these findings in a larger cohort and advance to Phase II, the KIR‑CAR approach could become a template for next‑generation solid‑tumor therapies, attracting biotech investors and prompting larger pharmaceutical collaborations. Moreover, the ability to target mesothelin—a widely expressed antigen in multiple aggressive cancers—offers a versatile platform that may be adapted to other tumor types, potentially reshaping the competitive landscape of cellular oncology.